MAPT and Alzheimer disease: et al had identified that p300-induced tau K174 acetylation, which is an early change in AD brains, can be inhibited by C646 and SA; Administration of SA rescued tau-induced memory deficits and prevented hippocampal atrophy in mouse models, suggesting that Targeting tau acetylation could be a new therapeutic strategy against human tauopathies 16.